Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor–Positive Allosteric Modulator, in Patients With Parkinson Disease

• Published in: Clinical pharmacology in drug development Vol. 11; no. 3; pp. 324 - 332
• Main Authors: Wilbraham, Darren, Biglan, Kevin M., Svensson, Kjell A., Tsai, Max, Pugh, Melissa, Ardayfio, Paul, Kielbasa, William
• Format: Journal Article
• Language: English
• Published: 01.03.2022

Mevidalen (LY3154207) is a positive allosteric modulator of the dopamine D1 receptor that enhances the affinity of dopamine for the D1 receptor. The safety, tolerability, motor effects, and pharmacokinetics of mevidalen were studied in patients with Parkinson disease. Mevidalen or placebo was given...